Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Axonyx Inc (AXYX) -- Ignore unavailable to you. Want to Upgrade?

To: Jack Hartmann who wrote (3)	1/7/2004 10:07:18 AM
From: VIXandMore	Read Replies (1) \| Respond to of 22

09:36 AXYX called #1 near-term idea at Sandler; target $15 (4.97 +0.07) Sandler & Co names Axonyx as their #1 idea going into next week's JP Morgan Healthcare conference (co presents on Jan 13), with a $15 target; firm is hearing that not only is the co's Phenserine (for Alzheimers) acting with the highest AChE specificity, but also acts as an APP inhibitor, and they believe that the drug may demonstrate an ability to stop or even reverse the process of Alzheimers, with a superior side effect profile. Also, firm would not be surprised if a major pharmaceutical commercial deal for Phenserine occurs in 1H04.